GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GSK PLC (XTER:GS71) » Definitions » Cyclically Adjusted Price-to-FCF

GSK (XTER:GS71) Cyclically Adjusted Price-to-FCF : 9.61 (As of Jun. 26, 2025)


View and export this data going back to 2007. Start your Free Trial

What is GSK Cyclically Adjusted Price-to-FCF?

As of today (2025-06-26), GSK's current share price is €16.43. GSK's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was €1.71. GSK's Cyclically Adjusted Price-to-FCF for today is 9.61.

The historical rank and industry rank for GSK's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

XTER:GS71' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 9.11   Med: 12.57   Max: 16.26
Current: 9.79

During the past years, GSK's highest Cyclically Adjusted Price-to-FCF was 16.26. The lowest was 9.11. And the median was 12.57.

XTER:GS71's Cyclically Adjusted Price-to-FCF is ranked better than
90.15% of 325 companies
in the Drug Manufacturers industry
Industry Median: 31.37 vs XTER:GS71: 9.79

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

GSK's adjusted free cash flow per share data for the three months ended in Mar. 2025 was €0.201. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €1.71 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


GSK Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for GSK's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GSK Cyclically Adjusted Price-to-FCF Chart

GSK Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.16 12.90 10.25 10.50 9.63

GSK Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.35 10.91 10.76 9.63 10.26

Competitive Comparison of GSK's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted Price-to-FCF falls into.


;
;

GSK Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

GSK's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=16.43/1.71
=9.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, GSK's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.201/136.1000*136.1000
=0.201

Current CPI (Mar. 2025) = 136.1000.

GSK Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.070 100.100 -0.095
201509 0.013 100.200 0.018
201512 0.287 100.400 0.389
201603 -0.038 100.400 -0.052
201606 0.247 101.000 0.333
201609 0.380 101.500 0.510
201612 0.666 102.200 0.887
201703 0.214 102.700 0.284
201706 0.115 103.500 0.151
201709 0.397 104.300 0.518
201712 0.624 105.000 0.809
201803 0.145 105.100 0.188
201806 0.283 105.900 0.364
201809 0.464 106.600 0.592
201812 0.972 107.100 1.235
201903 0.105 107.000 0.134
201906 0.212 107.900 0.267
201909 0.577 108.400 0.724
201912 0.783 108.500 0.982
202003 0.174 108.600 0.218
202006 0.652 108.800 0.816
202009 0.058 109.200 0.072
202012 0.904 109.400 1.125
202103 -0.007 109.700 -0.009
202106 0.213 111.400 0.260
202109 0.393 112.400 0.476
202112 0.933 114.700 1.107
202203 0.580 116.500 0.678
202206 0.270 120.500 0.305
202209 0.235 122.300 0.262
202212 0.324 125.300 0.352
202303 -0.132 126.800 -0.142
202306 0.220 129.400 0.231
202309 0.484 130.100 0.506
202312 0.680 130.500 0.709
202403 0.112 131.600 0.116
202406 0.192 133.000 0.196
202409 0.378 133.500 0.385
202412 0.347 135.100 0.350
202503 0.201 136.100 0.201

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GSK  (XTER:GS71) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


GSK Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of GSK's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GSK Business Description

Industry
Address
79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.

GSK Headlines

No Headlines